Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Tuesday, Citizens JMP initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Market Outperform rating and a price target of $28.00, joining other analysts who maintain a strong buy consensus with targets ranging from $28 to $42. The firm's analysts highlighted the company's development of novel precision therapeutics for CNS disorders, noting their unique approach through receptor-associated proteins (RAPs). According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt.
Rapport Therapeutics has been recognized for its efforts to create treatments that are more targeted and selective than traditional methods, which could lead to improved safety and tolerability profiles as well as broader therapeutic indexes. The company's lead candidate, RAP-219, has already shown safety, tolerability, and receptor occupancy in healthy adults. With a current ratio of 35.34, the company maintains substantial liquid assets to fund its development programs, though InvestingPro analysis indicates rapid cash utilization.
The biotechnology firm is in the midst of a Phase 2a proof-of-concept trial for RAP-219, with results expected in the third quarter of 2025. Citizens JMP analysts believe that RAP-219 has the potential to serve a significant portion of focal epilepsy patients who do not respond to existing treatments, estimating that 30%-40% of these patients are refractory.
The analysts project that RAP-219 could achieve a peak penetration of approximately 15% in this patient population, potentially generating net U.S. sales of around $1.1 billion by 2034. This projection is based on a 45% probability of success, as stated in their coverage initiation. The positive outlook on Rapport Therapeutics' stock reflects the anticipation of these developments in their drug pipeline.
In other recent news, Rapport Therapeutics has appointed Dr. Jeffrey Sevigny as its new chief medical officer. Dr. Sevigny brings over 15 years of experience in drug development, having previously held leadership roles at companies such as Prevail Therapeutics (NASDAQ:PRVL) and Eli Lilly (NYSE:LLY). At Prevail, he was key in achieving significant corporate milestones, including an IPO and its acquisition by Eli Lilly. In his new role at Rapport, Dr. Sevigny will focus on advancing the company's clinical strategy, particularly the RAP-219 program, which is currently in trials for conditions like focal epilepsy and bipolar mania. CEO Abraham N. Ceesay expressed confidence in Dr. Sevigny's ability to lead successful clinical programs and emphasized the importance of his expertise in neuroscience. Dr. Sevigny has highlighted the strong scientific foundation at Rapport and the transformative potential of RAP-219 in patient care. This appointment is part of Rapport's ongoing efforts to advance its precision neuroscience pipeline. The company has noted that its forward-looking statements are subject to risks and uncertainties, including clinical trial progress and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.